Jardiance ® (empagliflozin) to be studied for the treatment of people with chronic heart failure
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Jardiance ® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New Jardiance ® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
AHA 2017 Empagliflozin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 14, 2017 Category: Research Source Type: news
Synjardy XR Extended-release Tablets (Empagliflozin and Metformin Hydrochloride Extended-release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Grants Liraglutide Cardiovascular Events Indication FDA Grants Liraglutide Cardiovascular Events Indication
Liraglutide becomes the second glucose-lowering drug, after empagliflozin, to receive an additional indication for cardiovascular risk reduction.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Another Diabetes Drug Scores Heart Indication
(MedPage Today) -- Liraglutide follows empagliflozin into cardiovascular approval (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2017 Category: Urology & Nephrology Source Type: news
More Evidence Empagliflozin Protects the Kidneys More Evidence Empagliflozin Protects the Kidneys
New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Jardiance ® (empagliflozin) analysis reinforces established safety profile
An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lower limb amputations or bone fractures compared with placebo. The analysis, which includes the EMPA-REG OUTCOME® trial, was published this month in Advances in Therapy.(1) (Source: World Pharma News)
Source: World Pharma News - July 6, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
June ’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly ’s empagliflozin trial
A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic k … (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news
Boehringer reports positive safety profile of Jardiance for type 2 diabetes
Boehringer Ingelheim has reported a positive safety profile of oral Jardiance (empagliflozin) for the treatment of adults with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news
Jardiance analysis reinforces established safety profile
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 3, 2017 Category: Research Source Type: news
CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes
Some see the newly revealed cardiovascular benefits as rendering canagliflozin essentially"interchangeable" with empagliflozin, while others view the amputation signal as a deal breaker.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Boehringer and Lilly to assess empagliflozin for chronic kidney disease
Boehringer Ingelheim, in collaboration with Eli Lilly and Company, is set to evaluate empagliflozin in a new clinical outcomes trial to treat patients suffering from chronic kidney disease. (Source: Drug Development Technology)
Source: Drug Development Technology - June 13, 2017 Category: Pharmaceuticals Source Type: news
Empagliflozin to be studied in chronic kidney disease
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 12, 2017 Category: Research Source Type: news
